Published in Curr Treat Options Oncol on April 01, 2001
Study on Clinical Features and Outcomes of Breast Sarcoma (Breast-Sarc) | NCT04749446
Primary fibrosarcoma of the breast: a case report. J Breast Cancer (2011) 0.76
A Scary Onset of a Rare and Aggressive Type of Primary Breast Sarcoma: A Case Report. Case Rep Oncol (2016) 0.75
Primary Stromal Sarcoma of Breast: A Rare Entity. Iran J Pathol (2017) 0.75
High calcium concentrations shift the mode of exocytosis to the kiss-and-run mechanism. Nat Cell Biol (1999) 3.40
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet (2000) 3.25
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol (2001) 3.06
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
Extraskeletal osteosarcoma. A clinicopathologic review of 26 cases. Cancer (1990) 2.56
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol (1997) 2.32
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
Minority cancer patients and their providers: pain management attitudes and practice. Cancer (2000) 2.13
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer (1974) 2.10
Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol (2006) 1.91
Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer (2001) 1.89
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol (2012) 1.81
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer (1995) 1.65
Salmonella focal intracranial infections: review of the world literature (1884-1984) and report of an unusual case. Rev Infect Dis (1986) 1.61
Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg (1990) 1.59
Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer (1998) 1.57
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer (2001) 1.57
Tamoxifen-induced female androgenetic alopecia in a patient with breast cancer. Ann Intern Med (1997) 1.51
Soft tissue sarcomas of the head and neck in adolescents and adults. Am J Surg (1986) 1.50
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Adriamycin cardiomyopathy--risk factors. Cancer (1977) 1.46
Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol (1998) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol (1999) 1.45
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol (2011) 1.42
Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol (2010) 1.42
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst (1991) 1.40
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol (1994) 1.39
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer (2011) 1.38
Combination chemotherapy in adult desmoid tumors. Cancer (1993) 1.36
Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res (1977) 1.36
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol (1997) 1.34
Patterns of recurrence in extremity liposarcoma: implications for staging and follow-up. Cancer (1999) 1.31
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Role of radiotherapy in sarcoma of the breast--a retrospective review of the M.D. Anderson experience. Radiother Oncol (1999) 1.29
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol (1984) 1.28
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol (2001) 1.28
Sarcoma of the breast: implications for extent of therapy. The M. D. Anderson experience. Surgery (1994) 1.28
Doxorubicin-induced congestive heart failure in adults. Cancer (1985) 1.26
Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol (1999) 1.25
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer (1993) 1.25
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol (1999) 1.25
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int (2009) 1.22
Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature. Cancer Treat Rep (1977) 1.21
Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology (2001) 1.21
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol (2008) 1.21
Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA (1988) 1.20
Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther (1973) 1.19
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer (2005) 1.18
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol (1994) 1.17
Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol (2001) 1.17
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist (2001) 1.17
Extraskeletal myxoid chondrosarcoma. Long-term experience with chemotherapy. Am J Clin Oncol (1995) 1.15
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol (2013) 1.14
Myxoid liposarcoma. Experience with chemotherapy. Cancer (1994) 1.13
Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer (1993) 1.09
Arterial occlusion: management of giant cell tumor and aneurysmal bone cyst. AJR Am J Roentgenol (1981) 1.09
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol (2009) 1.07
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg (2001) 1.06
Conventional and dedifferentiated parosteal osteosarcoma. Diagnosis, treatment, and outcome. Cancer (1996) 1.05
Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol (1997) 1.04
Malignant melanoma of soft parts (clear cell sarcoma). A study of 17 cases, with emphasis on prognostic factors. Cancer (1990) 1.03
Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer (2001) 1.02
Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 1.01
Epithelioid sarcoma: results of conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2001) 1.01
Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother Pharmacol (1982) 1.00
Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol (1995) 1.00
Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf (2000) 0.99
Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol (1994) 0.99
A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol (1996) 0.99
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol (1992) 0.99
Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. Ann Thorac Surg (1991) 0.98
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1996) 0.98
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep (1979) 0.98
Ectopic production of the beta-subunit of human chorionic gonadotropin in osteosarcoma. Arch Pathol Lab Med (1989) 0.98
Sarcoma of the stomach: clinicopathologic study of 43 cases. J Surg Oncol (1980) 0.97
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol (1995) 0.97
Primary extraskeletal osteosarcoma--experience with chemotherapy. J Natl Cancer Inst (1995) 0.97
A phase II trial of taxol in metastatic melanoma. Cancer (1990) 0.97
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol (2000) 0.96
A 15-year experience with chemotherapy of patients with paraganglioma. Cancer (1995) 0.96
The natural history of resectable metastatic melanoma (Stage IVA melanoma). Cancer (1982) 0.96
Mesenteric laceration complicating a Heimlich maneuver. Ann Emerg Med (1986) 0.95
Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res (1983) 0.95
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res (1984) 0.94
The natural history of metastatic synovial sarcoma: experience of the Southwest Oncology group. Clin Orthop Relat Res (1982) 0.94
Successful treatment of hypoglycemia using glucagon in a patient with an extrapancreatic tumor. Ann Intern Med (1990) 0.93
Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol (2008) 0.93
Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol (2009) 0.93
Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. Br J Cancer (2009) 0.93
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol (2001) 0.92
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J (2001) 0.92
Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol (1982) 0.92
Recovery of sperm production after chemotherapy for osteosarcoma. Cancer (1989) 0.92
Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat (2011) 0.91